A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Recruiting now · Phase 1/Phase 2

Conditions studied: Endometrial Cancer

In brief

This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.

Key facts

Study ID
NCT04486352
Run by
Alliance Foundation Trials, LLC.
People needed
148
Starts
2021-10-20
Expected to finish
2027-10-01
Last updated by the study team
2026-04-01

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.